Thrombotic microangiopathies – availability of diagnostic methods and treatment options in the Czech Republic in 2021: results of a syndicated survey among clinical haematologists

Czech version

Authors: J. Gumulec ^1-3; M. Lánská ^3,4; I. Hrachovinová ^3,5; P. Salaj ^3,5; Z. Kořístek ^1,2; I. Demel ^1,2; D. Buff ^1,2; L. Broskevičová ^1,2; M. Pulcer ^2,6; P. Kovářová ^2,7; J. Martínek ^2,8; P. Žák ^2,3
Authors‘ workplace: Klinika hematoonkologie LF OU a FN Ostrava ¹; Centrum pro trombotické mikroangiopatie Ostrava ²; Česká skupina pro trombotické mikroangiopatie ³; IV. interní hematologická klinika FN Hradec Králové ⁴; Ústav hematologie a krevní transfuze Praha ⁵; Ústav laboratorní medicíny, LF OU a FN Ostrava ⁶; Krevní centrum FN Ostrava ⁷; Oddělení imunologie a alergologie, Zdravotní ústav se sídlem v Ostravě ⁸
Published in: Transfuze Hematol. dnes,29, 2023, No. Supplementum 3, p. 7-15.
Category:
doi: https://doi.org/10.48095/cctahd20233S7

Overview

From September to October 2021, at the request of the Centre for Thrombotic Microangiopathies Ostrava (C4TMO) and the Czech Group for Thrombotic Microangiopathies (CS4TMA), an online survey prepared by IQVIA based on CS4TMA data was conducted among clinical haematologists to verify the awareness of clinical haematologists about the rules and availability of care for patients with thrombotic microangiopathies. The professional basis for the development of the questionnaire was the formulation of good clinical practice guidelines for the care of patients with thrombotic thrombocytopenic purpura. A total of 49 interviews were conducted. The results of the survey indicate very good clinical practice for the care of patients with acute thrombotic microangiopathy at the respondents‘ institutions. However, the spectrum of departments that participated in the survey does not correspond to the actual spectrum of haematology departments in the Czech Republic. In particular, data from small outpatient clinics within type II hospitals or outside hospitals are missing.

Keywords:

thrombotic microangiopathies – thrombotic thrombocytopenic purpura – haemolytic-uremic syndrome – HELLP syndrome – archiving of biological material – exchange plasmapheresis – ADAMTS13 – PLASMIC score – French score – complement

Sources

1.0Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339 (22): 1585–1594. doi: 10.1056/NEJM199811263392203.

2.0Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997; 89 (9): 3097–3103.

3.0George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371 (19): 1847–1848. doi: 10.1056/NEJMc14 10951.

4.0Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347 (8): 589–600. doi: 10.1056/NEJMra020528.

5.0Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966; 45: 139–159.

6.0Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008; 142 (5): 819–826. doi: 10.1111/j.1365-2141.2008.07276.x.

7.0Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991; 325 (6): 393–397. doi: 10.1056/NEJM199108083250604.

8.0Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014; 29 (3): 148–167. doi: 10.1002/jca.21 302.

9.0Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group. Transfusion. 1992; 32 (8): 710–714.

10.0Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol: CJASN. 2010; 5 (10): 1844–1859. doi: 10.2215/CJN.02210310.

11.0Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol: JASN. 2007; 18 (8): 2392–2400. doi: 10.1681/asn.2006080811.

12.0Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36 (6): 673–681. doi: 10.1055/s-0030-1262890.

13.0Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int. 2016; 90 (5): 974–984. doi: 10.1016/ j.kint.2016.06.009.

14.0Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol (Berlin, Germany). 2016; 31 (1): 15–39. doi: 10.1007/s004 67-015-3076-8.

15.0Winters JL. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology Am Soc Hematol Educ Prog. 2017; 2017 (1): 632–638. doi: 10.1182/asheducation-2017. 1.632.

16.0Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015; 35 (5): 421–447. doi: 10.1016/j.nefro.2015.07.005.

17.0Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017; 15 (2): 312–322. doi: 10.1111/jth.13571.

18.0Scully M. Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy. Hematology Am Soc Hematol Educ Prog. 2017; 2017 (1): 651–659. doi: 10.1182/asheducation-2017.1.651.

19.0Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016; 14 (Suppl 11): 2–15.

20.0Zini G, d‘Onofrio G, Briggs C, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Labor Hematol. 2012; 34 (2): 107–116. doi: 10.1111/j.1751-553X.2011.01380.x.

21.0Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016; 14 (Suppl 1): 19. doi: 10.1186/s12959-016-0114-0.

22.0Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Prog. 2016; 2016 (1): 217–225. doi: 10.1182/asheducation-2016.1.21.7

23.0Williams LA, Marques MB, Education Committee of the Academy of Clinical Laboratory, Scientists. Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). Am J Clin Pathol. 2016; 145 (2): 158–165. doi: 10.1093/ajcp/aqv086.

24.0Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Medicale (Paris, France: 1983). 2012; 41 (3 Pt 2): e115–e135. doi: 10.1016/j.lpm.2011.11.013.

25.0Angioi A, Fervenza FC, Sethi S, et al. Diagnosis of complement alternative pathway disorders. Kidney Int. 2016; 89 (2): 278–288. doi: 10.1016/j.kint.2015.12.003.

26.0Gavriilaki E, Yuan X, Ye Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015; 125 (23): 3637–3646. doi: 10.1182/blood-2015-02-629683.

27.0Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: State of the art. Mol Immunol. 2015; 67 (1): 31–42. doi: 10.1016/ j.molimm.2015.03.246.

28.0Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009; 7 (4): 529–536. doi: 10.1111/j.1538-7836.2009.03285.x.

29.0Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158 (3): 323–335. doi: 10.1111/j.1365-2141.2012.09167.x.

30.0Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124 (11): 1715–1726. doi: 10.1182/blood- 2014-02-558296.

31.0Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost. 2015; 13 (2): 293–302. doi: 10.1111/jth.12790.

32.0Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nature reviews. Nephrology. 2012; 8 (11): 622–633. doi: 10.1038/nrneph. 2012.195

33.0Kolev M, Kemper C. Detection of cell membrane-bound CD46 using flow cytometry. Methods Mol Biol. 2014; 1100: 329–339. doi: 10.1007/978-1-62703-724-2_27.

34.0Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017; 4 (4): e157-e164. doi: 10.1016/S2352-3026 (17) 30026-1.

35.0Upadhyay VA, Geisler BP, Sun L, et al. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. Br J Haematol. 2019; 186 (3): 490–498. doi: 10.1111/bjh.15932.

36.0Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience. PLoS One. 2010; 5 (4): e10208. doi: 10.1371/journal.pone.0010208.

37.0Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18 (10): 2486–2495. doi: 10.1111/jth.15006.

38.0Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368 (23): 2169–2181. doi: 10.1056/ NEJMoa1208981

39.0Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017; 390 (10095): 681–696. doi: 10.1016/S0 140-6736 (17) 30062-4.

40.0Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar N. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol (Berlin, Germany). 2019; 34 (11): 2261–2277. doi: 10.1007/s00467-018-4091-3.

41.0Zheng XL, Vesely SK, Cataland SR, et al. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18 (10): 2503–2512. doi: 10.1111/jth.15009

42.0Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18 (10): 2496–2502. doi: 10.1111/jth.15010.

43.0Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol. 2013; 2 (3): 56–76. doi: 10.5527/wjn.v2.i3.56.

44.0Jokiranta TS. HUS and atypical HUS. Blood. 2017; 129 (21): 2847–2856. doi: 10.1182/blood- 2016-11-709865.

45.0Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005; 295 (6–7): 405–418. doi: 10.1016/j.ijmm.2005.06.009.

46.0Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365 (9464): 1073–1086. doi: 10.1016/S0140-6736 (05) 711 44-2.

47.0Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical hemolytic uremic syndrome. J Ather Thromb. 2019; 26 (2): 99–110. doi: 10.5551/jat.RV17026.

48.0Oh J, Oh D, Lee SJ, et al. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res. 2019; 54 (3): 218–228. doi: 10.5045/br.2019.54.3.218.

49.0Puraswani M, Khandelwal P, Saini H, et al. Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol. 2019; 10: 1282. doi: 10.3389/fimmu. 2019.01282.

50.0Richards A, Kathryn Liszewski M, Kavanagh D, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007; 44 (1–3): 111–122. doi: 10.1016/j.molimm.2006.07.004.

51.0Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015; 125 (21): 3253–3262. doi: 10.1182/blood- 2014-09-600411.

52.0Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014; 123 (24): 3733–3738. doi: 10.1182/blood-2013-12-547067.

53.0Nguyen MH, Mathew JJ, Denunzio TM, Carmichael MG. Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawaii J Med Public Health. 2014; 73 (9 Suppl 1): 22–24.

54.0Raina R, Sethi SK, Dragon-Durey MA, et al. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol (Berlin, Germany). 2022; 37 (7): 1479–1493. doi: 10.1007/s00467-022-05451-2.

55.0Mörtzell M, Berlin G, Nilsson T, et al. Analyses of data of patients with thrombotic microangiopathy in the WAA registry. Transf Apher Sci. 2011; 45 (2): 125–131. doi: 10.1016/ j.transci.2011.07.001.

56.0Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. Med Clin North Am. 2017; 101 (2): 395–415. doi: 10.1016/j.mcna. 2016.09.010.

57.0Spindler JS. Subclavian vein catheterization for apheresis access. J Clin Apher. 1983; 1 (4): 202–205. doi: 10.1002/jca.2920010403.

58.0Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant. 2010; 10 (9): 2142–2147. doi: 10.1111/j.1600-6143.2010.03228.x.

59.0Kalantari K. The choice of vascular access for therapeutic apheresis. J Clin Apher. 2012; 27 (3): 153–159. doi: 10.1002/jca.21225.

60.0Golestaneh L, Mokrzycki MH. Vascular access in therapeutic apheresis: update 2013. J Clin Apher. 2013; 28 (1): 64–72. doi: 10.1002/jca. 21267.

61.0Tanhehco YC, Zantek ND, Alsammak M, et al. Vascular access practices for therapeutic apheresis: results of a survey. J Clin Apher. 2019; 34 (5): 571–578. doi: 10.1002/jca.21 726.

62.0McGonigle AM, Patel EU, Waters KM, et al. Solvent detergent treated pooled plasma and reduction of allergic transfusion reactions. Transfusion. 2020; 60 (1): 54–61. doi: 10.1111/trf. 15600.

Labels

Haematology Internal medicine Clinical oncology

Editorial

Věnování

Archiving of biological material collected in patients with acute attack of thrombotic microangiopathy

Evaluation of blood counts and schistocytes in the peripheral blood smear

Complement system – disorders and diagnostics

Hereditary thrombotic thrombocytopenic purpura

Article was published in

Transfusion and Haematology Today

2023 Issue Supplementum 3